Teva tumbles on rival’s favorable drug results

Company's share price plunged after Biogen reported data from its oral multiple sclerosis drug, BG-12, a rival to Laquinimod.

April 21, 2011 22:30
2 minute read.
Teva Pharmaceutical Industries.

Teva Pharmaceutical Industries. . (photo credit: Ariel Jerozolimski)


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analysis from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief


The share price of Teva Pharmaceutical Industries Ltd. tumbled 10 percent to $44.25 in premarket trading on the Nasdaq Thursday after rival Biogen Idec Inc. reported positive data from its Phase III clinical trial of its oral multiple sclerosis drug, BG-12, and shares jumped 21 percent in pre-market trading on Thursday. BG-12 is a rival to Teva’s Laquinimod.

The last time that Teva’s share traded at $45 was in May 2009, during the rally that began in March 2009 following the global financial crisis.

In a conference call following the financial report for the first quarter, Biogen executives said that BG-12 cut the proportion of patients who relapsed by 49% and reduced the rate of progression by 38% after two years compared with placebo.

Clal Finance analyst Jonathan Kreizman told Globes, “For a long time, Teva has been building market expectations that Laquinimod will be a dominant drug in its field. Today’s information shows that it has a worthy rival in addition to Gilenya, developed by Novartis AG.”

Biogen sells two drugs that compete against Teva’s Copaxone: Avonex and Tysabri. Biogen's BG-12 will complete against Laquinimod, which is due to reach the market in 2012.

Copaxone had over $3 billion in sales in 2010, accounting for a third of Teva’s profits. The map of multiple sclerosis treatments is changing as oral drugs come on the market and Copaxone will likely lose its high standing.

At the 63rd American Academy of Neurology conference in Honolulu earlier this month, Biogen presented positive data about BG-12, as did Teva about Laquinimod. On Thursday, Biogen CEO Dr.

George Scangos was optimistic about BG-12, mentioning the positive results in the clinical trial.

It seems that investors considered Scangos’ optimism as reason to be worried about Teva. Bernstein Research analyst Roni Gal said that the good results of BG-12 puts it in a good position against Laquinimod and other oral multiple sclerosis drugs.

He said that BG-12 results were close to those achieved by Novartis’s Gilenya, which is already on the market. However, he is cautious about the lack of safety profiles for the drug, and he believes Laquinimod will find its place in the market.

According to Biogen’s financial report, Avonex had $642.5 million in sales in the first quarter and Tysabri had $251.4 million.

Teva will publish its financial report for the first quarter on May 11.

Teva's share price fell 1.7% on the TASE to NIS 165.50, before Biogen Idec’s announcement.

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection


Cookie Settings